Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Average Rating of "Hold" by Brokerages

Key Points

• Analysts give Kestra Medical Technologies a consensus “Hold” rating (1 sell, 1 hold, 3 buy) with a one‑year average price target of $27.40, though firms range from Goldman Sachs’ $17 neutral to BTIG’s $32 buy and Weiss’ sell (d‑).
• Insiders have been selling stock — director Brian Daniel Webster sold 15,000 shares at an average $20.04 on April 15 (45,000 shares sold in the past 90 days) — and insiders now own about 3.60% of the company.
• Recent results show a slight EPS miss (reported -$0.61 vs. -$0.60 expected) but strong revenue growth (+62.7% YoY); the company remains unprofitable with a negative net margin and a market cap around $1.2 billion.

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have received a consensus rating of "Hold" from the five ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $27.40.

A number of brokerages have commented on KMTS. The Goldman Sachs Group decreased their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a "neutral" rating on the stock in a report on Thursday, April 9th. BTIG Research reaffirmed a "buy" rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a report on Tuesday, April 7th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the company's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $20.04, for a total transaction of $300,600.00. Following the completion of the sale, the insider directly owned 349,786 shares in the company, valued at approximately $7,009,711.44. This represents a 4.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 45,000 shares of company stock worth $988,650. Corporate insiders own 3.60% of the company's stock.

Institutional Trading of Kestra Medical Technologies

Institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Kestra Medical Technologies during the 3rd quarter valued at $562,000. Jennison Associates LLC lifted its position in shares of Kestra Medical Technologies by 15.0% during the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company's stock valued at $5,817,000 after acquiring an additional 28,573 shares during the period. TD Asset Management Inc lifted its position in shares of Kestra Medical Technologies by 17.3% during the 3rd quarter. TD Asset Management Inc now owns 92,306 shares of the company's stock valued at $2,193,000 after acquiring an additional 13,588 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of Kestra Medical Technologies during the 3rd quarter valued at $48,000. Finally, Russell Investments Group Ltd. lifted its position in shares of Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock worth $41,000 after buying an additional 474 shares during the last quarter.

Kestra Medical Technologies Stock Performance

Shares of NASDAQ KMTS opened at $20.55 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. The stock's fifty day moving average price is $21.34 and its two-hundred day moving average price is $24.20. Kestra Medical Technologies has a one year low of $13.25 and a one year high of $30.00. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -5.19 and a beta of 0.82.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The firm had revenue of $24.55 million during the quarter. The company's revenue for the quarter was up 62.7% compared to the same quarter last year. On average, equities analysts forecast that Kestra Medical Technologies will post -2.34 EPS for the current year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.